Cell No. : Cell Name RCB1032 : NOS-1  update : 2024/02/20
Comment			Osteoid producing in vitro and in nude mice.
Comment from the depositor
Terms and conditions			There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC.
Remarks
Order Form			Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)
			Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
	Basic information	Depositor	Motoyama, Teiichi
		Originator	Hotta, Tetsuo & Motoyama, Teiichi
		Year of deposit	1994
		Animal	_human < Mammals
		Genus	Homo
		Species	sapiens
		Race	Japanese
		Gender	Male
		Age at sampling	16 years
		Tissue	bone
		Disease name	osteosarcoma
		Metastatic ability	Yes
		Metastatic tissue	lung
		Classification	cancer
		Year of origin	1989
		Lifespan	infinite
		Morphology	other
		Cellosaurus(Expasy)	CVCL_1610
			deposit info	lot info
		Medium	Medium List
		Culture type		Adherent cells
		Culture medium		RPMI1640 + 10% FBS
		Antibiotics		Free
		Passage method		0.25% Trypsin
	Culture information	Passage ratio		1 : 8 split
		SC frequency		Subculture : once/1-2 weeks, Medium Renewal : 2 times/week
		Temperature		37 ℃
		CO2 concentration		5 %
		Freeze medium		Medium + 10% DMSO
		Freezing method		Slow freezing
		Mycoplasma		(-)
		Virus (HIV)		(-)
		Isozyme		LD, NP
		Chromosome mode		66-135(50) : 66(6),67(4),68(2),69(9),70(13),71(6)/
		STR(human)		OK
Images			deposit info	lot info
Reference information		Reference	3
		User's Publication	25

Top

Reference

16680  Kusabe Y, Kawashima H, Ogose A, Sasaki T, Ariizumi T, Hotta T, Endo N.  Effect of temozolomide on the viability of musculoskeletal sarcoma cells  Oncol Lett  2015  10(4):2511-2518  PubMed ID: 26622881   DOI: 10.3892/ol.2015.3506

1936  Motoyama T, Hotta T, Watanabe H, Kumanishi T, Ichikawa T, Sekiguchi M  Differetial production of interleukin 6 in human osteosarcoma cells and the possible effects on neoplastic bone metabolism  Virchows Arch B Cell Pathol  1993  63:277-281  PubMed ID: 8100098   DOI: 10.1007/bf02899273

1935  Hotta T, Motoyama T, Watanabe H  Three human osteosarcoma cell lines exhibiting different phenotypic expressions.  Acta Pathol Jpn  1992  42:595-603  PubMed ID: 1449054   DOI: 10.1111/j.1440-1827.1992.tb03110.x

Top

User's Publication

17357  Hayashi T, Yamamoto N, Kurosawa G, Tajima K, Kondo M, Hiramatsu N, Kato Y, Tanaka M, Yamaguchi H, Kurosawa Y, Yamada H, Fujita N.  A Novel High-Throughput Screening Method for a Human Multicentric Osteosarcoma-Specific Antibody and Biomarker Using a Phage Display-Derived Monoclonal Antibody  Cancers (Basel)  2022  14(23):5829  PubMed ID: 36497311   DOI: 10.3390/cancers14235829

13409  Hirozane T, Masuda M, Sugano T, Sekita T, Goto N, Aoyama T, Sakagami T, Uno Y, Moriyama H, Sawa M, Asano N, Nakamura M, Matsumoto M, Nakayama R, Kondo T, Kawai A, Kobayashi E, Yamada T.  Direct conversion of osteosarcoma to adipocytes by targeting TNIK.  JCI Insight  2021    PubMed ID: 33400690   DOI: 10.1172/jci.insight.137245

20022  Rathore R, Caldwell KE, Schutt C, Brashears CB, Prudner BC, Ehrhardt WR, Leung CH, Lin H, Daw NC, Beird HC, Giles A, Wang WL, Lazar AJ, Chrisinger JSA, Livingston JA, Van Tine BA.  Metabolic compensation activates pro-survival mTORC1 signaling upon 3-phosphoglycerate dehydrogenase inhibition in osteosarcoma.  Cell Rep  2021  34(4):108678  PubMed ID: 33503424   DOI: 10.1016/j.celrep.2020.108678

13253  Fujiwara S, Kawamoto T, Kawakami Y, Koterazawa Y, Hara H, Takemori T, Kitayama K, Yahiro S, Kakutani K, Matsumoto T, Matsushita T, Niikura T, Koyanagi-Aoi M, Aoi T, Kuroda R, Akisue T.  Acquisition of cancer stem cell properties in osteosarcoma cells by defined factors.  Stem Cell Res Ther  2020    PubMed ID: 33008481   DOI: 10.1186/s13287-020-01944-9

7043  Ando T, Kudo Y, Iizuka S, Tsunematsu T, Umehara H, Shrestha M, Matsuo T, Kubo T, Shimose S, Arihiro K, Ogawa I, Ochi M, Takata T.  Ameloblastin induces tumor suppressive phenotype and enhances chemosensitivity to doxorubicin via Src-Stat3 inactivation in osteosarcoma.  Sci Rep  2017  7:40187  PubMed ID: 28054649   DOI: 10.1038/srep40187

10039  Takahashi K, Setoguchi T, Tsuru A, Saitoh Y, Nagano S, Ishidou Y, Maeda S, Furukawa T, Komiya S.  Inhibition of casein kinase 2 prevents growth of human osteosarcoma.  Oncol. Rep.  2017  37:1141-1147  PubMed ID: 27959425   DOI: 10.3892/or.2016.5310

7459  Tsuru A, Setoguchi T, Matsunoshita Y, Nagao-Kitamoto H, Nagano S, Yokouchi M, Maeda S, Ishidou Y, Yamamoto T, Komiya S.  Hairy/enhancer-of-split related with YRPW motif protein 1 promotes osteosarcoma metastasis via matrix metallopeptidase 9 expression.  Br. J. Cancer  2015  112:1232-40  PubMed ID: 25742474   DOI: 10.1038/bjc.2015.84

6426  Igawa K, Xie MF, Ohba H, Yamada S, Hayashi Y.  D-glucosamine conjugation accelerates the labeling efficiency of quantum dots in osteoblastic cells.  Biomed Res Int  2014  2014:821607  PubMed ID: 24818156   DOI: 10.1155/2014/821607

6427  Kobayashi E, Satow R, Ono M, Masuda M, Honda K, Sakuma T, Kawai A, Morioka H, Toyama Y, Yamada T.  MicroRNA expression and functional profiles of osteosarcoma.  Oncology  2014  86(2):94-103  PubMed ID: 24457375   DOI: 10.1159/000357408

6428  Arai K, Sakamoto R, Kubota D, Kondo T.  Proteomic approach toward molecular backgrounds of drug resistance of osteosarcoma cells in spheroid culture system.  Proteomics  2013  13(15):2351-60  PubMed ID: 23712969   DOI: 10.1002/pmic.201300053

6431  Shibuya H, Hamamura K, Hotta H, Matsumoto Y, Nishida Y, Hattori H, Furukawa K, Ueda M, Furukawa K.  Enhancement of malignant properties of human osteosarcoma cells with disialyl gangliosides GD2/GD3.  Cancer Sci  2012  103(9):1656-64  PubMed ID: 22632091   DOI: 10.1111/j.1349-7006.2012.02344.x

7968  Matsunoshita Y, Ijiri K, Ishidou Y, Nagano S, Yamamoto T, Nagao H, Komiya S, Setoguchi T.  Suppression of osteosarcoma cell invasion by chemotherapy is mediated by urokinase plasminogen activator activity via up-regulation of EGR1.  PLoS ONE  2011  6:e16234  PubMed ID: 21283769   DOI: 10.1371/journal.pone.0016234

8031  Iizuka S, Kudo Y, Yoshida M, Tsunematsu T, Yoshiko Y, Uchida T, Ogawa I, Miyauchi M, Takata T.  Ameloblastin regulates osteogenic differentiation by inhibiting Src kinase via cross talk between integrin beta1 and CD63.  Mol. Cell. Biol.  2011  31:783-92  PubMed ID: 21149578   DOI: 10.1128/MCB.00912-10

18257  Hirotsu M, Setoguchi T, Sasaki H, Matsunoshita Y, Gao H, Nagao H, Kunigou O, Komiya S.  Smoothened as a new therapeutic target for human osteosarcoma  Mol Cancer  2010  9:5  PubMed ID: 20067614   DOI: 10.1186/1476-4598-9-5

5180  Sasaki H, Setoguchi T, Matsunoshita Y, Gao H, Hirotsu M, Komiya S.  The knock-down of overexpressed EZH2 and BMI-1 does not prevent osteosarcoma growth.  Oncol Rep  2010  23(3):677-84  PubMed ID: 20127006   DOI: 10.3892/or_00000684

8566  Morioka K, Tanikawa C, Ochi K, Daigo Y, Katagiri T, Kawano H, Kawaguchi H, Myoui A, Yoshikawa H, Naka N, Araki N, Kudawara I, Ieguchi M, Nakamura K, Nakamura Y, Matsuda K.  Orphan receptor tyrosine kinase ROR2 as a potential therapeutic target for osteosarcoma.  Cancer Sci.  2009  100:1227-33  PubMed ID: 19486338   DOI: 10.1111/j.1349-7006.2009.01165.x

6435  Yamaguchi U, Honda K, Satow R, Kobayashi E, Nakayama R, Ichikawa H, Shoji A, Shitashige M, Masuda M, Kawai A, Chuman H, Iwamoto Y, Hirohashi S, Yamada T.  Functional genome screen for therapeutic targets of osteosarcoma.  Cancer Sci  2009  100(12):2268-74  PubMed ID: 19725836   DOI: 10.1111/j.1349-7006.2009.01310.x

6437  Maehara H, Kaname T, Yanagi K, Hanzawa H, Owan I, Kinjou T, Kadomatsu K, Ikematsu S, Iwamasa T, Kanaya F, Naritomi K.  Midkine as a novel target for antibody therapy in osteosarcoma.  Biochem Biophys Res Commun  2007  358(3):757-62  PubMed ID: 17506984   DOI: 10.1016/j.bbrc.2007.04.183

6438  Osaka E, Suzuki T, Osaka S, Yoshida Y, Sugita H, Asami S, Tabata K, Sugitani M, Nemoto N, Ryu J.  Survivin expression levels as independent predictors of survival for osteosarcoma patients.  J Orthop Res  2007  25(1):116-21  PubMed ID: 17034065   DOI: 10.1002/jor.20291

6439  Miyazawa K, Kakazu N, Ohyashiki K.  Clinical features of hypereosinophilic syndrome: FIP1L1-PDGFRA fusion gene-positive disease is a distinct clinical entity with myeloproliferative features and a poor response to corticosteroid.  Int J Hematol.  2007  85(1):5-10  PubMed ID: 17261495   DOI: 10.1532/IJH97.06047

3271  Matsunaga T, Yanagiguchi K, Yamada S, Ohara N, Ikeda T, Hayashi Y.  Chitosan monomer promotes tissue regeneration on dental pulp wounds.  J Biomed Mater Res A  2006  76:711-20  PubMed ID: 16315192   DOI: 10.1002/jbm.a.30588

6440  Osaka E, Suzuki T, Osaka S, Yoshida Y, Sugita H, Asami S, Tabata K, Hemmi A, Sugitani M, Nemoto N, Ryu J.  Survivin as a prognostic factor for osteosarcoma patients.  Acta Histochem Cytochem  2006  39(3):95-100  PubMed ID: 17327929   DOI: 10.1267/ahc.06005

2703  Ohara, Naoko, Hayashi, Yoshihiko, Yamada, Shizuka, Kim, Se-Kwon, Matsunaga, Tsunenori, Yanagiguchi, Kajiro, Ikeda, Takeshi  Early gene expression analyzed by cDNA microarray and RT-PCR in osteoblasts cultured with water-soluble and low molecular chitooligosaccharide.  Biomaterials  2004  25:1749-54  PubMed ID: 14738837   DOI: 10.1016/j.biomaterials.2003.08.022

2704  Yamada S, Ohara N, Hayashi Y.  Mineralization of matrix vesicles isolated from a human osteosarcoma cell line in culture with water-soluble chitosan-containing medium.  J Biomed Mater Res A  2003  66:500-6  PubMed ID: 12918032   DOI: 10.1002/jbm.a.10009

6453  Hanaoka E, Ozaki T, Nakamura Y, Moriya H, Nakagawara A, Sakiyama S.  Overexpression of DAN causes a growth suppression in p53-deficient SAOS-2 cells.  Biochem Biophys Res Commun  2000  278(1):20-6  PubMed ID: 11071849   DOI: 10.1006/bbrc.2000.3758